Novo Nordisk announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche announced a ...

Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...

Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.

Alix Steel and Paul Sweeney harness the power of Bloomberg Intelligence to analyze market news and provide in-depth company and industry research.

Novo Stock- Kepler Cheuvreux’s analyst upgrades Novo Nordisk to ‘buy,’ predicting a 24% gain after a 50% drop from its peak.

The major indexes suffered another week of sharp losses as Trump tariffs ramped up, shrugging off tame inflation.

In a shift in international diplomacy, the U.S. Department of Agriculture (USDA) has reached out to Denmark to ask whether the country can supply more eggs as the United States faces an ongoing ...